2024
Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings?
Palacios C, Chowdhary V, Hao R, Danve A, Malinis M. Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings? PLOS ONE 2024, 19: e0306337. PMID: 38959249, PMCID: PMC11221665, DOI: 10.1371/journal.pone.0306337.Peer-Reviewed Original ResearchConceptsInterferon-gamma release assayDisease-modifying antirheumatic drugsInterferon-gamma release assay testLatent tuberculosis infectionNon-endemic settingsRheumatologic diseasesRisk factorsPositive interferon-gamma release assayLatent tuberculosis infection screeningLatent tuberculosis infection diagnosisPositive IGRA testMonths of rifampinLow-risk patientsRetrospective chart reviewTNF-alpha inhibitorsTB risk factorsTargeted LTBI screeningOutpatient rheumatology clinicDisease-modifying drugsIGRA testPatient demographicsAdult patientsChart reviewAntirheumatic drugsNon-endemic areas
2023
1478. Evaluation Of Anal Cancer Screening Program in men who have sex with men (MSM) persons with HIV (PWH) At Two academic center HIV Clinics 2018-2022
Achhra A, Chan E, Applebaum S, Guerrero M, Hao R, Pantel H, Virata M, Barakat L. 1478. Evaluation Of Anal Cancer Screening Program in men who have sex with men (MSM) persons with HIV (PWH) At Two academic center HIV Clinics 2018-2022. Open Forum Infectious Diseases 2023, 10: ofad500.1314. PMCID: PMC10677807, DOI: 10.1093/ofid/ofad500.1314.Peer-Reviewed Original ResearchAnal dysplasiaAbnormal PapHIV clinicAnal cancer screening programsAmbulatory HIV clinicRetrospective chart reviewHistory of smokingCancer screening programsSquamous cell carcinomaAnal cytologyAntiretroviral therapyHIV careChart reviewClinic visitsMedian ageMultivariable analysisCell carcinomaScreening programPrior historyAge 35High riskType of insuranceBackground treatmentCharacteristics of peoplePWHExpanded or Risk Factor-Based Annual Screening for Hepatitis C Virus (HCV) Among Persons With HIV: Which Is the Best Approach?
Hao R, Brooks R, Zelenev A, Spinner G, Barakat L, Villanueva M. Expanded or Risk Factor-Based Annual Screening for Hepatitis C Virus (HCV) Among Persons With HIV: Which Is the Best Approach? Health Promotion Practice 2023, 24: 1009-1017. PMID: 37439817, DOI: 10.1177/15248399231169794.Peer-Reviewed Original ResearchConceptsHepatitis C virusRisk factor-based screeningElectronic medical recordsHIV clinicAnnual screeningC virusRisk factorsScreening siteAnnual screening ratesNew HCV diagnosesClinical decision support toolRisk factor assessmentPublic health expertsHCV testingHCV casesClinical decision supportHCV diagnosisHCV testScreening ratesProspective studyMedical recordsPositivity ratePositive casesUnprotected sexClinic
2022
1897. The Decline of Respiratory Viruses During the SARS-CoV-2 Pandemic: Public Health Interventions vs. Viral Competition?
Malik W, Hao R, Shepherd J. 1897. The Decline of Respiratory Viruses During the SARS-CoV-2 Pandemic: Public Health Interventions vs. Viral Competition? Open Forum Infectious Diseases 2022, 9: ofac492.1524. DOI: 10.1093/ofid/ofac492.1524.Peer-Reviewed Original ResearchYale New Haven Health SystemSARS-CoV-2SARS-CoV-2 pandemicNon-pharmaceutical interventionsRespiratory virusesInfluenza A/BSARS-CoV-2 infectionSARS-CoV-2 testPositive RSV testRates of influenzaSeasonal respiratory virusesPublic health interventionsWeekly testsCOVID-19 databasePre-pandemic dataRSV testPre-pandemic levelsPositivity rateInfluenza APositive testNegative testSame periodHealth interventionsAge groupsRelaxation of NPIsDo Cultures From Percutaneously Drained Intra-abdominal Abscesses Change Treatment? A Retrospective Review
Esposito A, Zhang Y, Nagarkatti N, Laird W, Coppersmith N, Reddy V, Leeds I, Mongiu A, Longo W, Hao R, Pantel H. Do Cultures From Percutaneously Drained Intra-abdominal Abscesses Change Treatment? A Retrospective Review. Diseases Of The Colon & Rectum 2022, 66: 451-457. PMID: 36538708, DOI: 10.1097/dcr.0000000000002644.Peer-Reviewed Original ResearchConceptsIntra-abdominal abscessPercutaneous drainAntimicrobial therapyLos pacientesAbdominal abscessSingle university-affiliated institutionRetrospective medical record reviewEmpiric antibiotic regimensSolid organ transplantsMedical record reviewUniversity-affiliated institutionCulture dataAntibiotic coursesAbdominal infectionAntibiotic regimensActive smokersMedian ageActive chemotherapyRecord reviewEvidence-based practiceMedian lengthUtility of cultureFemale sexIntraoperative culturesInclusion criteria
2018
Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients
Ogbuagu O, Hao R, Virata M, Villanueva MS, Malinis M. Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients. F1000Research 2018, 6: 620. PMID: 30344999, PMCID: PMC6171717, DOI: 10.12688/f1000research.11397.2.Peer-Reviewed Original ResearchHCV genotype 1 infectionGenotype 1 infectionHCV viral loadSOF/LDVViral loadSVR 12Treatment regimenGenotype 1Sustained virologic response 12 weeksYale New Haven Health SystemIU/HCV co-infected patientsVirologic response 12 weeksCo-infected patientsHCV treatment regimenMono-infected patientsSimilar viral loadsCompletion of therapyHCV genotype 1HIV viral loadSame treatment regimenSofosbuvir/ledipasvirStudy eligibility criteriaAntiretroviral therapyHCV infection
2017
Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients
Ogbuagu O, Hao R, Virata M, Villanueva M, Malinis M. Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients. F1000Research 2017, 6: 620. DOI: 10.12688/f1000research.11397.1.Peer-Reviewed Original ResearchHCV genotype 1 infectionGenotype 1 infectionHCV viral loadSOF/LDVViral loadSVR 12Treatment regimenGenotype 1Sustained virologic response 12 weeksYale New Haven Health SystemIU/HCV co-infected patientsVirologic response 12 weeksCo-infected patientsHCV treatment regimenMono-infected patientsSimilar viral loadsCompletion of therapyHCV genotype 1HIV viral loadSame treatment regimenSofosbuvir/ledipasvirStudy eligibility criteriaAntiretroviral therapyHCV infection
2013
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results
Kumar P, DeJesus E, Huhn G, Sloan L, Small CB, Edelstein H, Felizarta F, Hao R, Ross L, Stancil B, Pappa K, Ha B, for the SUPPORT Study Team. Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results. BMC Infectious Diseases 2013, 13: 269. PMID: 23741991, PMCID: PMC3685599, DOI: 10.1186/1471-2334-13-269.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlkynesAnti-HIV AgentsBenzoxazinesBiomarkersC-Reactive ProteinCarbamatesCyclopropanesDideoxynucleosidesDrug CombinationsFemaleFibrin Fibrinogen Degradation ProductsFibrinogenFuransHIV InfectionsHumansInterleukin-6LamivudineMaleMiddle AgedOrganophosphatesPlasminogenProspective StudiesRitonavirSulfonamidesVascular Cell Adhesion Molecule-1Young AdultConceptsSoluble vascular adhesion molecule-1Fosamprenavir/ritonavirAbacavir/lamivudineAntiretroviral therapyD-dimerInterleukin-6Cardiovascular biomarkersWeek 96Hs-CRPWeek 4High-sensitivity C-reactive proteinInitiation of ARTTreatment-related grade 2HIV-1-infected populationVascular adhesion molecule-1Percentage of patientsTraditional risk factorsWeeks of treatmentC-reactive proteinHIV-1 RNAMajor resistance mutationsGeometric mean ratiosAdhesion molecule-1Backbone therapyEfavirenz 600
2010
SUPPORT: 48‐week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under‐represented, antiretroviral‐naïve patients
Kumar P, DeJesus E, Huhn G, Sloan L, Garcia F, Small C, Edelstein H, Felizarta F, Hao R, Ha B, Stancil B, Ross L, Oie K, Pappa K. SUPPORT: 48‐week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under‐represented, antiretroviral‐naïve patients. Journal Of The International AIDS Society 2010, 13: p7-p7. PMCID: PMC3113075, DOI: 10.1186/1758-2652-13-s4-p7.Peer-Reviewed Original Research